Skip to content
August 15, 2022

Equity.Guru

Investment information for the new generation

SEEL.Q

We’re not out of the woods yet, but the major indices are turning green again and psychedelics, recently a relative investment pariah, are getting some love from investors. The…
Welcome to Equity.Guru’s Roundtable where our writers weigh in on the pros and cons of a spotlight company, break out where they see value, and help you avoid public…
Another Psychedelics article, and once again I try to answer the question: is it time to buy the dips in Psychedelics. My views remain the same. In this market,…
SPL026 Small Pharma (DMT.V), a psychedelics company focusing on DMT announced today it’s completed Phase 1 for its drug candidate SPL026, (a DMT derivative) for the treatment of Major…